Trial Profile
A Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ricolinostat (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Acetylon Pharmaceuticals
- 06 Feb 2020 Status changed from recruiting to completed.
- 16 May 2017 Planned number of patients changed from 80 to 40.
- 16 May 2017 Planned End Date changed from 10 Mar 2017 to 10 Dec 2019.